XM does not provide services to residents of the United States of America.
V
V

Victrex

Trade Ideas

Traders Sentiment

Technical Summary

Hourly

News

Bunzl, Equinor ASA, L'Oreal

EUROPE RESEARCH ROUNDUP-Bunzl, Equinor ASA, L'Oreal Oct 14 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bunzl, Equinor ASA and L'Oreal, on Monday. HIGHLIGHTS * Adidas AG ADSGn.DE : UBS raises target price to EUR 279 from EUR 275 * Bunzl BNZL.L : JP Morgan raises to overweight from neutral * Equinor ASA EQNR.OL : Morgan Stanley raises to equal weight from underweight * L'Oreal OREP.PA : Citigroup cuts target price to EUR 420 from
A
A
A
B
B
B
D
D
E
G
G
H
H
I
K
L
L
O
P
S
V
V
W
A
A
B
D
G
I
Y

Bank of Georgia, Tracsis, Victrex

EUROPE RESEARCH ROUNDUP- Bank of Georgia, Tracsis, Victrex Aug 29 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Bank of Georgia, Tracsis and Victrex, on Thursday. HIGHLIGHTS * Bank of Georgia BGEO.L : Peel Hunt raises target price to 6,200p from 6,000p * Close Brothers Group Plc CBRO.L : RBC raises to outperform from sector perform * Rathbones Group RAT.L : RBC raises target price to 1,950p from 1,850p * Tracsis Plc TRCS.L : Bere
A
B
B
B
C
C
E
E
E
E
G
G
I
I
N
R
R
V
H
G

Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine

BUZZ-Top of the Street: UCB, Moncler, Sonova, Moncler, Voestalpine A round-up of notable broker activity this morning from Europe's top-ranked* analysts: ** JP Morgan raises UCB UCB.BR to "overweight" from "neutral" as it sees the Belgian biotech firm's "superior growth profile" as "significantly" undervalued by the market; cites expected acceleration in Bimzelx growth ** Morgan Stanley downgrades Sonova SOON.S to "underweight" from "equal-weight", flagging the hearing aid maker's EV/EBITA valua
M
S
U
V
V

Admiral, UCB SA, Victrex

EUROPE RESEARCH ROUNDUP-Admiral, UCB SA, Victrex Aug 21 (Reuters) - Securities analysts revised their ratings and price targets on several European companies including Admiral, UCB SA and Victrex, on Wednesday. HIGHLIGHTS * Admiral ADML.L : RBC raises target price to 3,550p from 3,400p * Demant A/S DEMANT.CO : Morgan Stanley raises to overweight from underweight * UCB SA UCB.BR : JP Morgan raises to overweight from neutral * Victrex Plc VCTX.L : Jefferies raises to hold from underperform * Watki
A
A
C
H
I
M
N
R
S
S
U
V
V
A

AstraZeneca, Beazley, Puma

EUROPE RESEARCH ROUNDUP-AstraZeneca, Beazley, Puma Aug 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including AstraZeneca, Beazley and Puma on Monday. HIGHLIGHTS * AstraZeneca AZN.L : TD Cowen raises target price to 14,860p from 13,945p * Beazley BEZG.L : Jefferies raises target price to 1,020p from 975p * Puma SE PUMG.DE : Baader Helvea raises to buy from add * Quilter Plc QLT.L : Berenberg raises target price to 135p from 105p * WPP
A
B
B
B
D
D
E
H
J
J
L
L
M
M
O
P
S
S
U
V
W
A
A
B
B
R

Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.